Knockdown vs Knockout for lncRNA: Which Is More Informative?

Knockout is more informative about the locus; knockdown is more informative about the transcript.

If your claim is "this RNA regulates X", a knockdown (ASO or siRNA) plus rescue is stronger evidence than a deletion, because deletion removes DNA, transcription, and transcript together. If your claim is "this genomic region is required", the deletion is the right tool.

Most lncRNA papers want the first claim and run the second experiment.

The strongest practical combination for a transcript claim: knockdown + rescue + CRISPRi. Agreement between ASO and CRISPRi with a rescue points at the RNA; disagreement localizes the effect to transcription.

• • The locus contains annotated regulatory elements whose function you also care about.
• • You need a stable, heritable model rather than an acute perturbation.
• • The RNA is nuclear and ASO delivery is unreliable in your cell type.
• • You are screening many candidates and need clonal reagents.

• • The claim is about the RNA rather than the DNA.
• • The lncRNA is essential for viability, so knockout clones are unobtainable.
• • You need a time-resolved effect (hours) rather than a clonal endpoint.
• • You want to avoid clonal artifacts entirely.

Neither tool alone attributes a phenotype to the RNA. A rescue with an ASO-resistant (or siRNA-resistant) transcript does: if restoring the RNA restores the phenotype, the RNA is the functional unit.

Without rescue, the honest claim is locus-level. With rescue, it is transcript-level. That distinction is what most reviewers now ask for.

EDITGENE builds paired lncRNA models: knockout clones with sequenced breakpoints and CRISPRi lines from the same parental background, plus ASO-validated depletion and rescue derivatives.

Tell us the locus and the claim. Contact EDITGENE to request a project consultation or quote.

Tool performance varies with transcript localization, abundance, cell type, and delivery; the comparisons here describe evidential value rather than efficiency.

Transcript-level claims require a perturbation that preserves DNA and transcription, plus rescue; locus-level claims should be stated as such.

• • Liu SJ, et al. CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Science. 2017;355:eaah7111.
• • Crooke ST, et al. Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery. 2021;20:427–453.
• • Statello L, et al. Gene regulation by long non-coding RNAs and its biological functions. Nature Reviews Molecular Cell Biology. 2021;22:96–118.